| Metric | Q1 FY27 | Q4 FY26 | Q1 FY26 |
|---|---|---|---|
| Revenue from operations | 418.2 | 610.9 | 540.2 |
| Other income | 24.9 | 51.2 | 22.8 |
| Total income | 443.1 | 662.2 | 563.0 |
| Profit before exceptional items & tax | 144.6 | 276.9 | 186.2 |
| Exceptional items | 0.0 | -1.0 | 0.0 |
| Profit before tax | 144.6 | 277.9 | 186.2 |
| Net profit | 119.9 | 189.8 | 135.8 |
| Operating margin | 32.6% | 42.0% | 33.1% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | -11.70% |
|---|---|
| Net profit, quarter on quarter | -36.80% |
| Revenue, year on year | -22.60% |
| Operating profit, year on year | -15.90% |
| Operating profit, quarter on quarter | -31.50% |
NSE results filing, NSE: ANTHEM. Figures extracted from the filing.
Anthem Biosciences Ltd: key numbers
- Share price
- ₹873.60
- Market cap
- ₹49,201 Cr
- Revenue (annual)
- ₹2,124 Cr
- Net profit (annual)
- ₹591.8 Cr
- P/E (TTM)
- 85.4×Sector 50.4×
- Promoter holding
- 71.42%-3.26% QoQ
- FII holding
- 2.57%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Anthem Biosciences Ltd
All →Anthem Biosciences Other Announcement
Designated Person Viridity Tone LLP sold shares of Anthem Biosciences Ltd worth ₹82.67 Crore via market sale.
- Value
- ₹82.67 Cr
Anthem Biosciences Legal & Regulatory
Anthem Biosciences Ltd announced the settlement of an upside sharing amount of ₹127.68 Crore related to a prior divestment, following shareholder approval.
- Value
- ₹127.7 Cr
Anthem Biosciences Earnings Call Transcript: Key Takeaways
Revenue fell 25% YoY due to deferred deliveries, though management claims a record order book will drive second-half recovery. While EBITDA margins remain high at 39.6%, the quarter reflects high lumpiness in the CRDMO business.
Anthem Biosciences Investor Presentation: Key Takeaways
Anthem reported Q1FY27 revenue of ₹4,182 Mn with a 39.6% EBITDA margin. Results reflect timing shifts in deliveries, though management reports strong underlying demand and year-on-year margin improvement.
Anthem Biosciences Earnings Call: Key Takeaways
Anthem Biosciences delivered record Q4 performance with FY26 revenue of ₹2,280cr and 43.4% EBITDA margins, driven by CRDMO strength.
Anthem Biosciences Earnings Call: Key Takeaways
Anthem delivered robust FY26 growth, overcoming destocking challenges in their core CRDMO segment.